Lannett (NYSE:LCI) says in a filing that it’s entered into a new collaboration and license agreement with HEC.
The deal replaces an agreement in principle the two previously entered into, with respect to development, commercialization and distribution of HEC’s insulin glargine product in the United States.
In the deal, the two will share responsibility for an control of development; Lannett will pay development costs up to $32M and split amounts over that 50/50 for the next $13M in costs; HEC will make the product; and Lanentt will prepare the BLA filing that HEC will submit.
Also: Lannett will become exclusive distributor in the U.S. and have sole responsibility for commercializing it there; the two will share profits and losses for the first 10 years, and after that split 60/40 in favor of HEC; and Lannett will own IP rights tied to certain developed drug delivery devices associated with the product.
Knight Therapeutics’ (OTC:KHTRF) New Drug Submission (NDS) for BIJUVA has been accepted for review by Health Canada.
BIJUVA, estradiol and progesterone capsules, is licensed by Knight from TherapeuticsMD (NASDAQ:TXMD).
BIJUVA is a bio-identical hormone therapy combination of estradiol and progesterone in a single, daily oral capsule intended for the treatment of moderate-to-severe vasomotor symptoms associated with menopause in women with intact uteri.
Merck (NYSE:MRK) announces that Keytruda has been approved by the National Medical Products Administration in China as a lung cancer treatment.
The company says the approval is the third for first-line NSCLC in China.
Keytruda in combination with chemotherapy significantly was found to improve both overall survival and progression-free survival in patients with metastatic squamous non-small cell lung cancer.
MRK +0.53% premarket to $86.15.
Cresco Labs (OTCQX:CRLBF) announces the signing of a binding agreement for the sale-and-leaseback of two properties in Ohio and Michigan.
The deals will bring in non-dilutive funding of ~$38M for the company
Cresco Labs also announces the mutual termination of an agreement to acquire VidaCann.
“With the flexibility to continue to leverage non-dilutive funding options like sale-lease-back agreements, we are well-positioned to continue executing on our strategy to build the most important, enduring company in U.S. cannabis,” says Cresco Labs CEO Charlie Bachtell.
Boston Scientific’s (NYSE:BSX) subsidiary sells 50% of its Zytiga-related royalties to Ontario Municipal Employees Retirement System for $256M.
The sale doesn’t change the company’s 2019 forecast.
BSX gained the Zytiga royalty interests through its acquisition of BTG, which closed in August.
Boston Scientific plans to use the cash to pay down its debt.
